Tolerance Some patients do better on one medication than the other
An important note for GLP1 GI AEs is that standard approaches may not correctly characterise the incidence of GI AEs given the mechanism of action of GLP1 RAs, which decrease gastric emptying and suppress appetite to reduce overall food intake
Kokura Y et al
Your GLP-1 and GIP receptors have been activated at progressively higher levels
Trimethylamine N-oxide (TMAO): From Gut Microbiome Pathway to Cardiometabolic Risk Trimethylamine N-oxide (TMAO) is a gut microbiome-derived metabolite formed when dietary nutrients like choline, carnitine, and betaine are metabolized into trimethylamine (TMA) and subsequently oxidized in the liver
Legislative authorization for the wildly popular program lapsed in late 2024, and although its direct impact had been blunted due to language permitting FDA to award PRVs until September 30, 2026 so long as the underlying products had received RPD designations before December 20, 2024, uncertainty over the programs fate was beginning to weigh on product developers and investors alike
